Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
26 févr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
08 févr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
24 janv. 2024 02h30 HE
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
08 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
19 déc. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
06 déc. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
07 nov. 2023 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Endoscopy Procedures Market Size worth $53.19 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
26 sept. 2023 10h35 HE
|
The Insight Partners
Pune, India, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Endoscopy is a minimally invasive procedure used to examine a person's digestive tract through the mouth, anus, or in small incisions. The procedure...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 août 2023 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...